Resource Summary Report

Generated by RRID on Aug 28, 2026

Daudi

RRID:CVCL_0008
Type: Cell Line

Proper Citation

RRID:CVCL_0008

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0008

Proper Citation: RRID:CVCL_0008

Description: Cell line Daudi is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: EBV-related Burkitt lymphoma

Defining Citation: PMID:170370, PMID:216485, PMID:1325212, PMID:2052620, PMID:2140233, PMID:2470097, PMID:2985879, PMID:2998993, PMID:3026973, PMID:3034807, PMID:3080238, PMID:3100061, PMID:3116544, PMID:3159941, PMID:3518877, PMID:3785169, PMID:3874327, PMID:3905596, PMID:4122458, PMID:4174339, PMID:4178827, PMID:4321974, PMID:4364259, PMID:4878906, PMID:5021706, PMID:6186604, PMID:6200433, PMID:6231253, PMID:6286763, PMID:6500159, PMID:6547209, PMID:6582512, PMID:6592381, PMID:6806672, PMID:6935474, PMID:6954533, PMID:7316467, PMID:7849311, PMID:8176200, PMID:8197130, PMID:8301159, PMID:8515068, PMID:8558913, PMID:8558920, PMID:8568269, PMID:8847894, PMID:9192833, PMID:9473234, PMID:9510473, PMID:9685479, PMID:9737686, PMID:9738977, PMID:9973220, PMID:10739008, PMID:11021758, PMID:11226526, PMID:11894933, PMID:12145705, PMID:12967475, PMID:14504097, PMID:15028022, PMID:16957166, PMID:19358282, PMID:20164919, PMID:20215515, PMID:20454443, PMID:22460905, PMID:22885699, PMID:24590883, PMID:25355872, PMID:25485619, PMID:25877200, PMID:25960936, PMID:26589293, PMID:27397505, PMID:28196595, PMID:29892436, PMID:30285677, PMID:30629668, PMID:30894373, PMID:31068700, PMID:31160637, PMID:35839778

Comments: Caution: TP53 mutation indicated incorrectly as being at c.637C>T in PubMed=2052620., Population: African; Kenyan., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: Human variation panel., Part of: Human Protein Atlas, Cell Atlas panel., Part of: COSMIC cell lines project., Part of:

Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Daudi

Synonyms: DAUDI, NK-10A, NK-10a, NK 10a, NK10a, N, GM03190, GM3190, GM03190A, GM17346

Cross References: BTO:BTO_0001561, CLO:CLO_0002708, CLO:CLO_0013411, CLO:CLO_0013740, CLO:CLO_0050991, EFO:EFO_0002169, MCCL:MCC:0000141, CLDB:cl993, CLDB:cl994, CLDB:cl995, CLDB:cl996, CLDB:cl997, CLDB:cl998, CLDB:cl999, CLDB:cl5181, AddexBio:C0003010/4669, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ATCC:CCL-213, ATCC:CRL-7917, BCRC:60192, BioGRID_ORCS_Cell_line:1081, BioSample:SAMN00808283, BioSample:SAMN01821546, BioSample:SAMN01821623, BioSample:SAMN03472413, BioSample:SAMN10987948, cancercelllines:CVCL_0008, CCRID:1101HUM-PUMC000134, CCRID:1102HUM-NIFDC00053, CCRID:3101HUMTCHu140, CCRID:4201HUM-CCTCC00097, CCTCC:GDC0097, Cell_Model_Passport:SIDM00845, CGH-DB:9195-4, ChEMBL-Cells:CHEMBL3307579, ChEMBL-Targets:CHEMBL614281, CLS:302009, Coriell:GM03190, Coriell:GM17346, Cosmic:687838, Cosmic:906831, Cosmic:919135, Cosmic:929815, Cosmic:931102, Cosmic:932762, Cosmic:991548, Cosmic:996304, Cosmic:998716, Cosmic:1019315, Cosmic:1037701, Cosmic:1070708, Cosmic:1071878, Cosmic:1086326, Cosmic:1093789, Cosmic:1118470, Cosmic:1176616, Cosmic:1191690, Cosmic:1517663, Cosmic:1995384, Cosmic:2649240, Cosmic:2759407, Cosmic:2760061, Cosmic:2814537, Cosmic:2815216, Cosmic:2823073, Cosmic-CLP:906831, dbMHC:48767, DepMap:ACH-000786, DSMZ:ACC-78, DSMZCellDive:ACC-78, ECACC:85011437, ECACC:94071449, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, FANTOM5_SSTAR:10422-106C8, GDSC:906831, GEO:GSM99381, GEO:GSM862859, GEO:GSM862860, GEO:GSM862861, GEO:GSM862862, GEO:GSM886973, GEO:GSM888042, GEO:GSM960117, GEO:GSM960118, GEO:GSM960119, GEO:GSM960120, GEO:GSM1374459, GEO:GSM1669726, GEO:GSM3150242, GEO:GSM7701371, GEO:GSM7701372, IARC_TP53:143, IARC_TP53:21144, ICLC:HTL95024, IGRhCellID:Daudi, IHW:IHW09366, IPD-IMGT/HLA:10471, IZSLER:BS TCL 104, JCRB:JCRB9071, KCB:KCB 2012116YJ, KCLB:10213, LiGeA:CCLE_233, LINCS_LDP:LCL-2018, Lonza:490, NCBI_Iran:C112, PharmacoDB:Daudi_283_2019, PRIDE:PXD004181, PRIDE:PXD012087, PRIDE:PXD030304, Progenetix:CVCL_0008, PubChem_Cell_line:CVCL_0008, RCB:RCB1640, TKG:TKG 0362, Wikidata:Q54828579

ID: CVCL_0008

Record Creation Time: 20220427T215744+0000

Record Last Update: 20260815T232607+0000

Ratings and Alerts

No rating or validation information has been found for Daudi.

Warning: Discontinued: ATCC; CRL-7917
Caution: TP53 mutation indicated incorrectly as being at c.637C>T in PubMed=2052620., Population: African; Kenyan., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: Human variation panel., Part of: Human Protein Atlas, Cell Atlas panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 54 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Wang L, et al. (2026) A first-in-class bifunctional antibody targeting CD20 and CD37 remodels the immune microenvironment in relapsed or refractory B-cell malignancies. Journal of hematology & oncology, 19(1).

Alsina M, et al. (2026) Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study. Cancer immunology research, 14(4), 528.

Zhang Z, et al. (2026) A Moderate-Affinity Antibody-Drug Conjugate Targeting B7-H3 Exerts Potent Antitumor Efficacy. Pharmaceuticals (Basel, Switzerland), 19(4).

Yao H, et al. (2026) Zanubrutinib enhances CD19 CAR T killing of B-cell lymphoma by inhibiting BTK phosphorylation, regulating PI3K/AKT/mTOR pathway, and promoting autophagy. Blood science (Baltimore, Md.), 8(2), e00276.

Schneiderova P, et al. (2025) The SARS-CoV-2 trigger highlights host interleukin 1 genetics in Epstein-Barr virus reactivation. Cell reports, 44(7), 115859.

Domagala J, et al. (2025) Ammonia Suppresses the Antitumor Activity of Natural Killer Cells and T Cells by Decreasing Mature Perforin. Cancer research, 85(13), 2448.

Zhang M, et al. (2025) Structures of butyrophilin multimers reveal a plier-like mechanism for V?9V?2 T cell receptor activation. Immunity, 58(7), 1660.

Ogawa A, et al. (2025) Adenosine kinase and ADAL coordinate detoxification of modified adenosines to safeguard metabolism. Cell.

Jeong Y, et al. (2025) Dual targeting of EZH2 and PD-L1 in Burkitt's lymphoma enhances immune activation and induces apoptotic pathway. Frontiers in immunology, 16, 1578665.

Beauchemin H, et al. (2025) Inhibiting the RNA helicase DDX3X in Burkitt lymphoma induces oxydative stress and impedes tumor progression in xenografts. Frontiers in cell and developmental biology, 13, 1642006.

Kok N, et al. (2025) CD28 signaling domain boosts persistence and in vivo anti-tumor activity of stem cell-derived CD19-CAR-NK cells. iScience, 28(6), 112548.

Billon E, et al. (2025) BTN2A1 acquisition through trogocytosis enhances V?9V?2 T cell cytotoxicity against autologous and cancer cells. Cell reports, 44(10), 116387.

Chen Z, et al. (2025) YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies. Cell, 188(2), 331.

Krishnamoorthy M, et al. (2025) Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy. Frontiers in immunology, 16, 1518787.

Akhtar A, et al. (2025) Bioengineering the metabolic network of CAR T cells with GLP-1 and Urolithin A increases persistence and long-term anti-tumor activity. Cell reports. Medicine, 6(3), 102021.

Choi J, et al. (2024) Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. Cancer cell, 42(5), 833.

Yu WW, et al. (2024) Skin immune-mesenchymal interplay within tertiary lymphoid structures promotes autoimmune pathogenesis in hidradenitis suppurativa. Immunity, 57(12), 2827.

McNutt SW, et al. (2024) Phosphorylation-Driven Epichaperome Assembly: A Critical Regulator of Cellular Adaptability and Proliferation. Research square.

Takami M, et al. (2024) Anti-V?24J?18 TCR Antibody Tunes iNKT Cell Responses to Target and Kill CD1d-negative Tumors in an Fc?RII (CD32)-dependent Manner. Cancer research communications, 4(2), 446.

Pfeffer K, et al. (2024) A method for screening functional anti-Treg antibodies using a Treg-like cell line. Journal of leukocyte biology.